SCHEMBL13626474

SCHEMBL13626474

CC(C)C(O)c1cccc(S)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 3/20 0.46
HTR2A P28223 2/20 0.46
ADRB1 P08588 2/20 0.46
MIF P14174 1/20 0.46
HTR2B P41595 1/20 0.46
KDM4E B2RXH2 5/20 0.39
HIF1A Q16665 4/20 0.39
LMNA P02545 4/20 0.39
ADRA2C P18825 3/20 0.39
ADRA2A P08913 2/20 0.39
ALDH1A1 P00352 2/20 0.38
TSHR P16473 3/20 0.36
NFKB1 P19838 3/20 0.36
ALOX15 P16050 2/20 0.36
THPO P40225 2/20 0.36
HSD17B10 Q99714 2/20 0.36
CHRM2 P08172 1/20 0.36
RGS12 O14924 1/20 0.36
GLA P06280 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13934964 0.84 KMT2A (0.47) ADRA1AHTR2AADRB1MIFHTR2B
SCHEMBL6843601 0.84 ADRA1A (0.54) ADRA1AHTR2AADRB1MIFHTR2B
SCHEMBL21160722 0.79 PGK1 (0.37) ADRA1AHTR2AADRB1MIFHTR2B
SCHEMBL458729 0.79 HDAC4 (0.47) KDM4EHIF1ALMNAALDH1A1TSHR
SCHEMBL6055100 0.77 KDM4E (0.50) ADRA1AHTR2AADRB1MIFHTR2B
SCHEMBL28648350 0.77 HDAC4 (0.32) ADRA1AHTR2AADRB1MIFHTR2B
SCHEMBL13620753 0.76 ADRB1 (0.74) ADRA1AHTR2AADRB1MIFHTR2B
SCHEMBL6055386 0.76 ACHE (0.48) ADRA1AHTR2AADRB1MIFHTR2B
SCHEMBL24452119 0.76 ADRB1 (0.38) ADRA1AHTR2AADRB1MIFHTR2B
SCHEMBL10822537 0.76 ADRB1 (0.38) ADRA1AHTR2AADRB1MIFHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009142967-A1 THERAPEUTIC PROSTAGLANDIN COMPOUNDS USED AS OCULAR HYPOTENSIVE AGENTS ALLERGAN, INC. (US) 2009-11-26 WO disclosed